80% Still in Remission? MajesTEC-3 Myeloma Breakthrough Explained & More From ASH 2025 скачать в хорошем качестве

80% Still in Remission? MajesTEC-3 Myeloma Breakthrough Explained & More From ASH 2025

One of the most talked-about studies from ASH 2025 in multiple myeloma was MajesTEC-3, showing over 80% of patients in early relapse remained in remission at three years. In this video, Dr. Joseph Mikhael explains what that progression-free survival curve really means, how teclistamab and daratumumab work together, what MRD negativity tells us, and how bispecific antibodies may change frontline and post-CAR T treatment strategies. If you or a loved one is living with multiple myeloma, this breakdown of the latest research could help you understand where treatment is headed. Topics Covered in this Video: 0:00 - The MajesTEC-3 trial progression-free survival explained 0:23 - Introduction 0:50 - How bispecific antibodies work in multiple myeloma 1:07 - Teclistamab + daratumumab in early relapse 1:27 - 3-year remission data (80%+ PFS) 2:16 - Infection risks and updated safety protocols 2:43 - Frontline bispecific therapy results 3:37 - MRD negativity and linvoseltamab strategy 5:44 - Using bispecifics after CAR T-cell therapy (cevostamab / FcRH5) 6:52 - Treating extramedullary myeloma with combination therapy 7:46 - What this research means for patients now With all this groundbreaking new research, you may wonder, “how can I be part of the clinical trials that are moving the needle toward the cures for myeloma?” The IMF makes searching for clinical trials simple with our clinical trial matching engine. Visit www.myeloma.org/sparkcures to find a trial today. Have a question that needs more personalized support? Call us! We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at infoline@myeloma.org, or schedule your call at a time that works best for you at: https://www.myeloma.org/infoline. _______________ Founded in 1990, the International Myeloma Foundation (IMF) is the world’s leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: improving the quality of life of myeloma patients while working toward prevention and a cure. The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group® (IMWG)—a network of more than 300 internationally renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed across the globe. Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo®, its InfoLine staff, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes. The IMF is driven by its vision: A world where every myeloma patient can live life to the fullest, unburdened by the disease. Learn more at www.myeloma.org or contact the IMF InfoLine at (800) 452-CURE (2873) (U.S. & Canada), +1 (818) 487-7455 (worldwide), or infoline@myeloma.org. Subscribe to our channel:    / imfmyeloma   Find us online: Facebook: @myeloma |   / myeloma   X/Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.